The #Dfree device, wearable bladder ultrasound technology, is showing promise in predicting #UTIs for women with #MS. 🔗 Read more: ow.ly/gkTn50W3p4H #CMSC2025 #MultipleSclerosis DFree US #MS #Incontinence National MS Society Amer. Urol. Assn.

🚗 A new study reveals that over 50% of patients with multiple sclerosis discontinue infusion-based treatments due to travel-related challenges. ow.ly/J5o550W7v2T #MultipleSclerosis #CMSC2025 @MSSociety Novartis

The U.S. FDA granted Fast Track designation to #PMN310 (ProMIS Neurosciences), a monoclonal antibody that targets toxic #Aβ oligomers for the treatment of #Alzheimer’s. PMN310 may provide a lower risk of #ARIA. practicalneurology.com/news/amyloid-b… @Alzassociation American Academy of Neurology @ACPIMPhysician

Once daily oral #AD109 significantly reduced #OSA severity and improved oxygenation in the phase 3 #LunAIRo clinical trial. ow.ly/efUW50Wvwvg Apnimed Sleep Research Society World Sleep Society American Academy of Sleep Medicine #apnea

For people with #Parkinson disease and #dementia, #ambroxol treatment showed target engagement but did not improve cognitive outcomes—phase 2 study published in JAMA Neurology. practicalneurology.com/news/ambroxol-… American Academy of Neurology MDS Alzheimer's Association michaeljfox.org

Award recipients were recognized at #AAIC25 for their significant contributions to the field of #Alzheimer disease and #dementia. ow.ly/39u550WwIZe Alzheimer's Association American Academy of Neurology

The therapeutic eligibility window of #DMT Tx for early #Alzheimer disease may be predicted from baseline CDR-GS and MMSE scores, new findings presented at #AAIC2025 suggest. ow.ly/E9Te50WwIXz Alzheimer's Association UTokyo | 東京大学 American Academy of Neurology

Daily at-home #gamma stimulation treatment with the #Spectris device was shown to preserve brain structure and slow cognitive decline in people with #Alzheimer disease in data presented at #AACI2025. ow.ly/WYVe50Wx29U Cognito Therapeutics Alzheimer's Association American Academy of Neurology

A structured, high-intensity lifestyle intervention was linked to significant improvements in #cognitive measures for older adults at risk of #dementia. US POINTER study results presented at #AAIC2025. ow.ly/iYFK50Wx2nA Alzheimer's Association American Academy of Neurology

The @Alzassociation issued its first clinical practice guideline for the use of blood-based #biomarkers in #Alzheimer's diagnosis. Presented at #AAIC25. ow.ly/aFbB50Wxubb American Academy of Neurology @ACPIMPhysician

People with #Alzheimer's who carried the SIGMAR1 genotype showed greater clinical response after treatment with #blarcamesine, an oral sigma-1 receptor activator. #AAIC25 ow.ly/nYiI50WxwTC Alzheimer's Association American Academy of Neurology Anavex Life Sciences

Dr Jeff Cohen (Cleveland Clinic) discusses new #guidelines from ECTRIMS and EBMT on autologous hematopoietic stem cell transplantation for relapsing #Multiple_Sclerosis and #NMOSD in a new #MS Masters #podcast episode: ow.ly/OAVU50WMZYr National MS Society American Academy of Neurology CMSC

New Podcast Episode: Catherine Auriemma, MD, MSHP & Carolyn Chow, MD (Penn Medicine) provide insights on #Alzheimer's therapies from interviews with patients and caregivers. ow.ly/U2LT50WVnaT American Academy of Neurology Alzheimer's Association Penn Medicine MD University of Pennsylvania Neurology

🎧Check out LDI Fellow Catherine Auriemma of Penn Medicine on The Neurology Hub podcast.

Can DMTs be safely discontinued in people living with MS? Dr Jeff Cohen (Cleveland Clinic) discusses comprehensive recommendations from ECTRIMS for deescalating & discontinuing DMTs in people with #Multiple_Sclerosis. ow.ly/Ktxf50X1HtU CMSC National MS Society American Academy of Neurology

Expert Voices in #Dementia: Ana C. Pereira, MD (Icahn School of Medicine at Mount Sinai) discusses key takeaways from #AAIC2025 in a podcast episode, with updates in lifestyle medicine, #biomarkers, and DMTs. ow.ly/o8sa50XblGw Alzheimer's Association American Academy of Neurology Practical Neurology

#Multiple_sclerosis can be differentiated from #NMOSD & #MOGAD using plasma N-glycan #biomarker signatures—study results published in #Neurology: Neuroimmunology and Neuroinflammation. ow.ly/YVSY50Xo1JW Neurology Journal MS Focus: The Multiple Sclerosis Foundation National MS Society #MultipleSclerosis American Academy of Neurology

In people with relapsing #Multiple_Sclerosis, GFAP levels correlated with clinical and MRI outcomes, according to a post hoc analysis of the SUNBEAM and RADIANCE clinical trials. MS Focus: The Multiple Sclerosis Foundation National MS Society #MultipleSclerosis CMSC ow.ly/nTkm50XLFR3

Two new #MS subtypes found using MRI and sNfL levels with assistance of machine learning model according to study results published in Brain. #MultipleSclerosis National MS Society MS Assoc. of America MS Society UK ow.ly/8ryv50Y4PpL